Listed by the USPTO as BREEN, KIMBERLY CATHERINE
Tech Center 1600 • Art Units: 1651 1657 1675
This examiner grants 24% of resolved cases
BREEN, KIMBERLY CATHERINE is assigned to Tech Center 1600 and Art Unit 1651. Across 85 resolved cases, the allowance rate is 23.5% and the interview lift is 54.4%. The median time to allowance is 1294 days. The low allowance outcome and higher interview measure suggest that interviews may be particularly important when navigating a difficult prosecution record.
The leading companies are Danisco US Inc., CJ CheilJedang Corporation, and B. G. Negev Technologies and Applications Ltd. The leading firms are Meunier Carlin & Curfman LLC, TROUTMAN PEPPER LOCKE LLP, and Nevrivy Patent Law Group P.L.L.C. The median duration supports early preparation for interviews and carefully sequenced claim amendments.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18844384 | MUTANT L-THREONINE-RELEASING PROTEIN AND METHOD FOR PRODUCING L-THREONINE USING SAME | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 18023252 | COMPOSITION FOR FREEZE-PRESERVING MICROALGAE BELONGING TO FAMILY THRAUSTOCHYTRIACEAE AND METHOD FOR FREEZE-PRESERVING OF MICROALGAE BELONGING TO THRAUSTOCHYTRIACEAE USING SAME | Final Rejection | CJ CHEILJEDANG CORPORATION |
| 18681047 | METHOD FOR PRODUCTION OF AMMONIA, USING INORGANIC NANOPARTICLE-MICROBIAL COMPLEX | Final Rejection | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17628903 | WASHING AND CLEANING AGENTS HAVING IMPROVED ENZYME STABILITY | Non-Final OA | Henkel AG & Co. KGaA |
| 16826135 | POLYMERIC BIOCATALYSTS AND METHODS | Final Rejection | BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY |
| 18002438 | DIGITAL ANTIMICROBIAL SUSCEPTIBILITY TESTING | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18552599 | Clostridial Neurotoxins Comprising an Exogenous Activation Loop | Final Rejection | IPSEN BIOPHARM LIMITED |
| 18513092 | AMINOACYL TRANSFER RNA SYNTHETASES | Non-Final OA | Trustees of Tufts College |
| 18041975 | BLOOD CELL LYSING AGENT FOR ISOLATING BACTERIA FROM BLOOD CULTURE | Final Rejection | Becton, Dickinson and Company |
| 18566018 | METHODS AND COMPOSITIONS RELATED TO A MODIFIED METHYLTRANSFERASE | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18284252 | COLORIMETRIC BIOSENSOR, PREPARATION METHOD THEREOF, AND ANTIBIOTIC SUSCEPTIBILITY TESTING METHOD USING THE SAME | Final Rejection | INHA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 17172860 | COMPOSITIONS COMPRISING PROBIOTICS AND METHODS OF USE THEREOF | Final Rejection | Imagilin Technology LLC |
| 18687521 | LAUNDRY COMPOSITIONS FOR CLEANING | Non-Final OA | Danisco US Inc. |
| 17774437 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION IN BACILLUS CELLS | Final Rejection | DANISCO US INC. |
| 18176270 | METHODS AND KITS FOR DETECTING CROSS-CONTAMINATION IN FOODBORNE AND ENVIRONMENTAL PATHOGEN TESTING | Non-Final OA | Applied Food Diagnostics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy23.5% of resolved applications examined by Kimberly Catherine Breen were allowed (85 resolved cases), compared with 31.5% across Art Unit 1651 over the last five years.
This examiner's interview lift is +54.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kimberly Catherine Breen took 1,294 days on average from filing to allowance.
Kimberly Catherine Breen examines applications in Art Unit 1651 in Tech Center 1600 (Biotechnology & Pharmaceuticals).